Safety study of the drug OMS1620 in healthy volunteers
Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new drug called OMS1620 to see if it is safe and how the body processes it. It is for healthy adults who may join to help find out if the drug could be used for future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 32 on the body mass index (BMI) scale, and weigh at least 45 kg.
- If you are a woman, you cannot be pregnant or nursing, and you must be postmenopausal, surgically sterile, or use highly effective birth control.
- If you are a man and sexually active with a woman who can get pregnant, you must use two effective birth control methods.
- You must be in good health with no major medical problems, as confirmed by a doctor's exam and lab tests.
- You cannot have used certain steroid medications within the past few months, and you cannot currently be taking oral birth control pills.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication for children with classic congenital adrenal hyperplasia (CAH). It aims to see if the drug helps better control hormone levels and reduce the need for high doses of current steroid medicines.
This study tracks adults with congenital adrenal hyperplasia (a condition where the body can't make enough cortisol) who switch to a new form of hydrocortisone called modified-release. It looks at how well the medication works over time and its effects on daily life.
This study tests a new drug, atumelnant, for adults with classic congenital adrenal hyperplasia (CAH) caused by 21-OHD. It aims to see if it can help control hormone levels while allowing lower doses of current steroid medications.
This trial tests a new medicine (NBIP-01435) to see if it helps adults with classic congenital adrenal hyperplasia better manage their condition. The goal is to improve hormone levels and potentially allow for lower steroid doses.
This early study tests Lu AG13909 in people with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. It aims to see how the drug affects hormone levels and whether it is safe for different CAH hormone patterns.
This study tests the long-term safety and effectiveness of the study drug atumelnant for people with congenital adrenal hyperplasia. It is for those who have already completed a previous atumelnant study and may benefit from continuing treatment.
Hear when a new Congenital Adrenal Hyperplasia (CAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.